Trophoblast cell surface antigen 2 (Trop-2) is overexpressed in breast cancer, and antibody–drug conjugates against Trop-2, Sacituzumab govitecan, are approved by the US Food and Drug Administration (FDA) for patients with pre-treated metastatic breast cancer [10]. This evidence concerns the gene TACSTD2 and breast carcinoma.